Clinical Trials
431 trialsGDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
Eastern Cooperative Oncology Group
Vitamin D and Breast Cancer: Does Weight Make a Difference?
Stanford University
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
Thomas Jefferson University
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
TRANSCENDER
Spanish Breast Cancer Research Group
Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
University of Chicago
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
HeartPhone Cancer Survivors Trial 2019
Penn State University
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Dana-Farber Cancer Institute
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Baylor College of Medicine
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Breast-48
University of Virginia
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
ELPIS
Fundacio Clinic Barcelona
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
Stanford University
OTT15-04
Ottawa Hospital Research Institute
AMEERA-1
Sanofi
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Bolt Biotherapeutics, Inc.
A Study of PF-06873600 in People With Cancer
Pfizer
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast
University of Southern California
PAVO
Tempus AI
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
AXIL95
Institut Bergonié
TNBC
Zenith Epigenetics
3-D Super Resolution Ultrasound Microvascular Imaging
UNC Lineberger Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
National Cancer Institute (NCI)
Impact of Topical Tranexamic Acid in Breast Reconstruction
University of California, San Francisco
WI223281
Georgetown University
AMEERA-4
Sanofi
AMEERA-6
Sanofi
AMEERA-5
Sanofi
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Alaunos Therapeutics
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Alaunos Therapeutics
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
University of Texas Southwestern Medical Center
KATE3
Hoffmann-La Roche
PROACT
Washington University School of Medicine
eMonarcHER
Eli Lilly and Company
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
DESTINY-Breast01
Daiichi Sankyo
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
M.D. Anderson Cancer Center
TATEN
SOLTI Breast Cancer Research Group
PERSEVERE
Hoosier Cancer Research Network